It was an honor to meet Professor Mads Krogsgaard Thomsen to discuss the results from seven phase 3a PIONEER clinical trials for oral semaglutide in patients with type 2 diabetes, including the cardiovascular outcomes trial (PIONEER 6) at the highly anticipated symposium highlighted by the ADA 2019 annual meeting.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
Questions:
1. What are the advantages of oral semaglutide compared to existing glucagon-like peptide-1 (GLP-1) analogues? (0:05)
2. Could you give us an overview on the data on oral semaglutide that are being presented at this meeting? (0:36)
3. What were the findings of oral semaglutide on weight loss? (1:37)
4. The PIONEER studies investigated a number of combined therapeutic approaches. Which were the most promising? (2:24)
5. Which patients are most likely to benefit from oral semaglutide? (3:12)
Professor Mads Krogsgaard Thomsen has no conflicts of interest in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
